imidazopyridine derivatives
Recently Published Documents


TOTAL DOCUMENTS

46
(FIVE YEARS 4)

H-INDEX

11
(FIVE YEARS 0)

2021 ◽  
pp. 118379
Author(s):  
Leandro H. Zucolotto Cocca ◽  
André Pelosi ◽  
Lucas F. Sciuti ◽  
Luis M. G. Abegão ◽  
Kenji Kamada ◽  
...  


2021 ◽  
Vol 6 (4) ◽  
pp. 843-851
Author(s):  
Sharanya Kuthyala ◽  
Sareen Sheikh ◽  
G. K. Nagaraja ◽  
B. R. Kannika ◽  
S. Madan Kumar ◽  
...  


2020 ◽  
Author(s):  
Giovanni Petrarolo ◽  
Edoardo Gelardi ◽  
Giorgia Colombo ◽  
Francesca Picarazzi ◽  
Mattia Mori ◽  
...  


2020 ◽  
Vol 29 (9) ◽  
pp. 1643-1654
Author(s):  
Vellanki Ragha Suma ◽  
Reddymasu Sreenivasulu ◽  
Mandava Venkata Basaveswara Rao ◽  
Madala Subramanyam ◽  
Mohamed Jawed Ahsan ◽  
...  


2020 ◽  
Vol 32 (4) ◽  
pp. 776-782
Author(s):  
Ravindra S. Sonawane ◽  
Kiran D. Patil ◽  
Avinash V. Patil

A series of novel imidazopyridine derivatives as proton pump inhibitors was designed with compounds of CID data base and explored considering AZD0865 as standard. Many compounds were identified and docked in proton pump ATPase pocket (PDB ID: 4ux2). Molecular docking studies revealed that many compounds showed good proton pump ATPase inhibitory activity. The docking poses revealed the interaction of ligands with amino acid. The standard drug AZD0865 had docking score of -7.112302 and displayed interactions with Asn138 and Asp137. A series of novel imidazopyridine derivatives as proton pump inhibitors were docked, synthesized and characterized by IR, NMR, CHN and MS spectral analysis. The target imidazopyridines were prepared from substituted 2-aminonicotinic acid and 2-bromo-1-substituted ethanone. in vitro Studies explained that few compounds exhibited moderate to good proton pump ATPase inhibitory activity in comparison with the reference drugs i.e. AZD0865. Compounds 11 and 12 shown higher activities with the IC50 4.3. Compounds 1, 4, 6, 7, 8, 10 and 13 showed weak anti-ulcer activity with its IC50 5.2, 5.8, 5.5, 5.1, 4.9, 4.6 and 5.9 and positive control AZD0865 shown IC50 2.0.



2020 ◽  
Vol 32 (11) ◽  
pp. 2685-2692
Author(s):  
R.S. Sonawane ◽  
Mrunal Shirsat ◽  
S.R. Patil ◽  
J.C. Hundiwale ◽  
A.V. P atil

CID data base were explored considering AZD0865 as standard and docked in proton pump ATPase pocket (PDB ID: 4ux2) to find out novel imidazopyridine derivatives as proton pump inhibitors. A number of compounds showed good proton pump ATPase inhibitory activity as per the molecular docking study as compared to standard compound AZD0865. The compound AZD0865showed a docking score of -7.11 and revealed the interactions with amino acids Asn 138 and Asp 137. A series of novel imidazopyridine derivatives as proton pump inhibitors were docked, synthesized and characterized by IR, NMR, CHN and MS spectral analysis. The target imidazopyridines were prepared from the intermediate substituted 2-aminonicotinic acid and 2-bromo-1-substituted ethanone. in vitro pharmacological studies explained that some compounds exhibited moderate to good proton pump ATPase inhibitory activity in comparison with the reference drugs i.e. AZD0865. Compound N-(3-(aminomethyl)benzyl)-3-(benzylamino)-2-(o-tolyl)imidazo[1,2-a]pyridine-8-carboxamide and N-(3-(aminomethyl)benzyl)-3-(benzylamino)-2-(4-ethylphenyl)imidazo[1,2-a]pyridine-8-carboxamide showed higher activities with the IC50 6.2 and 6.0 μg. Many compounds showed IC50 as weak antiulcer activity as compared to positive control AZD0865.



2019 ◽  
Vol 45 (10) ◽  
pp. 5261-5290
Author(s):  
Zohreh Bakherad ◽  
Maliheh Safavi ◽  
Saghi Sepehri ◽  
Afshin Fassihi ◽  
Hojjat Sadeghi-Aliabadi ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document